Orchid Pharma share price today

Orchid Pharma Ltd's share price was ₹876.75 at the close on 4 November 2026. It has been rising for 20 weeks. That is 0.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹502 and ₹1,065, and at that close it sat 67% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Orchid Pharma Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

Over the last 11 years the share price moved +2,192% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

8 points on a year earlier.

1. Promoters raised their stake by 4.6 points in one quarter

   From 69.8% to 74.5% in the September 2026 quarter.

2. Operating margin up 6.8 points on a year earlier

   4.6% in the June 2026 quarter, from -2.1%.

   Why: It kept more of each rupee of sales after direct costs and held operating costs down.

   Next results: check whether core sales and earnings recover as management hopes.

   From the earnings call on 21 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Orchid Pharma reported revenue of ₹304 crore, up 15.6% from ₹263 crore a year earlier, and a profit of ₹3.22 crore, against a loss of ₹5.69 crore a year earlier.

Orchid Pharma results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Orchid Pharma's management discussed these results on a call held on 21 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Orchid Pharma closed at ₹876.75 on 4 November 2026, up 4.2% from ₹841.55 a year earlier (7 November 2025) and up 113.4% over five years. Its highest weekly close since March 2016 was ₹2,527.90 on 1 April 2021.

Orchid Pharma share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

497 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Orchid Pharma closed at ₹876.75, up 5.2% on the week and down 11.6% on the month. 21 Aug 2026: Orchid Pharma held its results call for April to June 2026. Management guided: 7-ACA project capital spending ₹750 crore; no significant additional capital spending planned next financial year; commissioning and first commercial batch planned for March 2027.

Earlier

• Results for April to June 2026: Revenue up 15.6% on a year earlier.

Orchid Pharma has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

No. Orchid Pharma Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 21 August 2026, Orchid Pharma's management guided: 7-ACA project capital spending ₹750 crore; no significant additional capital spending planned next financial year; commissioning and first commercial batch planned for March 2027.

“Rather than having Plan B, we decided to have a good Plan A.”Manish Dhanuka, on the call for April to June 2026

What management guided

• 7-ACA ramp-up planned at 80-100% by end of first year; long-term mix 80% in-house and 20% third-party, initially captive; PLI currently expected for two years.
• Cefiderocol commissioning planned for December 2026, with validation and initial batches during January-March 2027.
• India approval expected 6-9 months after facility readiness, subject to a DCGI clinical-trial waiver; WHO prequalification is also planned.
• US sterile-injectable roadmap remains guided to 2030; newer molecules may be submitted by end of next year, with launches not before 2028.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 21 August 2026.

When Orchid Pharma reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Regulated-market demand to improve over coming quarters - check whether core mix and earnings recovery strengthen as anticipated.

Orchid Pharma is on one of our India lists: Pharma stocks.

Orchid Pharma Ltd earned ₹3.2 Cr of net profit in the Jun 2026 quarter. Full-year FY26 profit was ₹10.0 Cr. That is 1.1% of the quarter's revenue. The same quarter a year earlier lost ₹5.7 Cr. 3 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹10.0 Cr (−92.6% on the year before).

On average over the last four quarters, profit changed −88.6% and revenue +13.3%. Profit is growing slower than sales: rising costs are taking part of the growth.

Orchid Pharma Ltd reported ₹304 Cr of revenue in the Jun 2026 quarter, +15.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 3.5% a year on average. The last full year, FY26, came in at ₹1,233 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,073 Cr.

FY26 revenue was ₹1,233 Cr, −11.8% on the year before.

Recent pace: the last four quarters grew +13.3% on average, against 3.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +14.1%, against +10.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −83.4%, against −69.0% a year (rolling over).

Orchid Pharma Ltd's operating margin was 4.6% in the Jun 2026 quarter, 6.8 percentage points higher than the same quarter a year ago. Across 13 years it has been between −6.0% and 20.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +6.8 percentage points on the year while gross margin changed +2.5 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 128% of Orchid Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹126 Cr of operating cash against ₹10.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹360 Cr of spending on assets, free cash was −₹234 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 128% of profit came in as cash: the cash cycle got 55 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 5.1× depreciation over three years. The next section checks what that spending is building.

Orchid Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 124 days in FY26, down from 179 days in FY21. It spent ₹605 Cr on assets over the last 3 years. Customers take 113 days to pay, and stock sits for 161 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,233 Cr, each day of that cycle ties up about ₹3.4 Cr, so roughly ₹419 Cr is tied up in the business at any time.

FY26: customers took 113 days to pay and stock sat for 161 days, about 5.3 months of sales sitting as stock, for a full cycle of 124 days, shorter than FY21's 179.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 161 days. Customers pay about 113 days after that. Suppliers are paid at 150 days. Together that makes the 124-day cycle.

Spending on assets: ₹605 Cr over the last 3 years, against ₹118 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹414 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Orchid Pharma Ltd's P/E is 290.5×, near the high end of its own history: higher than 79% of past readings. Its usual P/E (the middle reading) is 69.3×, over 3.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹2.10.